Literature DB >> 31835089

Methionine enkephalin inhibits influenza A virus infection through upregulating antiviral state in RAW264.7 cells.

Jing Tian1, Na Qu2, Xue Jiao3, Xiaonan Wang4, Jin Geng5, Noreen Griffin6, Fengping Shan7.   

Abstract

MENK, as an immune adjuvant, has potential immune-regulatory activity on innate and adaptive immune cells. The aim of this work was to investigate the antiviral effect of MENK on influenza virus-infected murine macrophage cells (RAW264.7) and its underlying mechanisms. The results showed that MENK markedly inhibited influenza A virus (H1N1) replication in pre- and post-MENK treatment, especially in pre-MENK treatment. The mechanisms exploration revealed that MENK (10 mg/mL) significantly inhibited the nucleoprotein (NP) of influenza virus and up-regulated levels of IL-6, TNF-α and IFN-β compared with those in H1N1 control group. Further experiments confirmed that antiviral effects of MENK was associated with promotion of opioid receptor (MOR) as well as activation of NF-κB p65 inducing cellular antiviral status. The data suggest that MENK should be potential candidate for prophylactic or therapeutic treatment against H1N1 influenza virus.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral effect; Influenza A virus; Methionine enkephalin; Opioid receptor; RAW264.7 cell; Toll-like receptors

Year:  2019        PMID: 31835089     DOI: 10.1016/j.intimp.2019.106032

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  2 in total

Review 1.  A "Drug-Dependent" Immune System Can Compromise Protection against Infection: The Relationships between Psychostimulants and HIV.

Authors:  María Amparo Assis; Pedro Gabriel Carranza; Emilio Ambrosio
Journal:  Viruses       Date:  2021-04-21       Impact factor: 5.048

Review 2.  Opioids Regulate the Immune System: Focusing on Macrophages and Their Organelles.

Authors:  Shaohua Wen; Yuan Jiang; Shuang Liang; Zhigang Cheng; Xiaoyan Zhu; Qulian Guo
Journal:  Front Pharmacol       Date:  2022-01-12       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.